# Qihan Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qihan-biotech

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.qihanbio.com
- Total disclosed funding: $100M
- Latest round: Series A (Mar 29, 2021)
- Investors on record: 10

## About

Established in 2017 and based in Hangzhou, China, Qihan Biotech is a biotechnology company that provides novel immune-privileged cell and organ therapies. The company's chairman, Steven Holtzman is a former CEO of Decibel Therapeutics, former EVP corporate development of Biogen, and founder of DNX. The company's founder & CEO, Luhan Yang holds a PhD in Human Biology and Translational Medicine from Harvard Medical School. She is the co-founder, former president & CSO of eGenesis, and co-inventor of CRISPR-Cas9 technologies. In September 2023, Qihan Biotech raised more than CNY 100 million in pre-series B funding from new investor Jinkong Capital.


The company builds an immune-privileged cell and organ platform to produce cells and organs that can evade immune attacks, such as natural killer cells for immune oncology, cardiomyocytes, neurons, and islet cells for regenerative medicine. It also produces animals with enhanced agronomical traits or multi-disease resistance in agriculture through multi-genome editing technology.

The company will use the funds to support product iteration and global development of gene-edited stem cell products.

## Funding rounds

- Series A, Mar 29, 2021, $67M — Hong Shan, Lilly Asia Ventures, CMB International Asset Management, MPC
- Series A, Sep 23, 2019, $26M — Hong Shan, NLVC, CMB International Asset Management, Legend Star, BC Capital
- Series A, Jul 23, 2018, $7.8M — Alta Partners, ARCH Venture Partners, Hong Shan, NLVC, Biomatics Capital Partners

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Hong Shan — Series A
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A
- Biomatics Capital Partners (https://capitalatlas.ai/funds/biomatics-capital-partners) — Series A
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series A
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A
- BC Capital — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- MPC — Series A